{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:59:04Z","timestamp":1790222344745,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The impact of immunosuppressive therapies on the efficacy of vaccines to SARS-CoV-2 is not completely clarified. We analyzed humoral and T cell-mediated response after COVID-19 mRNA vaccine in immunosuppressed patients and patients with common variable immunodeficiency disease (CVID).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients<\/jats:title>\n                <jats:p>We enrolled 38 patients and 11 healthy sex- and age-matched controls (HC). Four patients were affected by CVID and 34 by chronic rheumatic diseases (RDs). All patients with RDs were treated by corticosteroid therapy and\/or immunosuppressive treatment and\/or biological drugs: 14 patients were treated with abatacept, 10 with rituximab, and 10 with tocilizumab.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Total antibody titer to SARS-CoV-2 spike protein was assessed by electrochemiluminescence immunoassay, CD4 and CD4-CD8 T cell-mediated immune response was analyzed by interferon-\u03b3 (IFN-\u03b3) release assay, the production of IFN-\u03b3-inducible (CXCL9 and CXCL10) and innate-immunity chemokines (MCP-1, CXCL8, and CCL5) by cytometric bead array after stimulation with different spike peptides. The expression of CD40L, CD137, IL-2, IFN-\u03b3, and IL-17 on CD4 and CD8 T cells, evaluating their activation status, after SARS-CoV-2 spike peptides stimulation, was analyzed by intracellular flow cytometry staining. Cluster analysis identified cluster 1, namely the \u201chigh immunosuppression\u201d cluster, and cluster 2, namely the \u201clow immunosuppression\u201d cluster.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After the second dose of vaccine, only abatacept-treated patients, compared to HC, showed a reduced anti-spike antibody response (mean: 432\u00a0IU\/ml\u2009\u00b1\u2009562 vs mean: 1479\u00a0IU\/ml\u2009\u00b1\u20091051: <jats:italic>p<\/jats:italic>\u2009=\u20090.0034), and an impaired T cell response, compared with HC. In particular, we found a significantly reduced release of IFN-\u03b3 from CD4 and CD4-CD8 stimulated T cells, compared with HC (<jats:italic>p<\/jats:italic>\u2009=\u20090.0016 and <jats:italic>p<\/jats:italic>\u2009=\u20090.0078, respectively), reduced production of CXCL10 and CXCL9 from stimulated CD4 (<jats:italic>p<\/jats:italic>\u2009=\u20090.0048 and <jats:italic>p<\/jats:italic>\u2009=\u20090.001) and CD4-CD8 T cells (<jats:italic>p<\/jats:italic>\u2009=\u20090.0079 and <jats:italic>p<\/jats:italic>\u2009=\u20090.0006). Multivariable General Linear Model analysis confirmed a relationship between abatacept exposure and impaired production of CXCL9, CXCL10, and IFN-\u03b3 from stimulated T cells. Cluster analysis confirms that cluster 1 (including abatacept and half of rituximab treated cases) showed a reduced IFN-\u03b3 response, as well as reduced monocyte-derived chemokines All groups of patients demonstrated the ability to generate specific CD4 T activated cells after spike proteins stimulation. After the third dose of vaccine, abatacept-treated patients acquired the ability to produce a strong antibody response, showing an anti-S titer significantly higher compared to that obtained after the second dose (<jats:italic>p<\/jats:italic>\u2009=\u20090.0047), and comparable with the anti-S titer of the other groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Patients treated with abatacept showed an impaired humoral immune response to two doses of COVID-19 vaccine. The third vaccine dose has been demonstrated to be useful to induce a more robust antibody response to balance an impaired T cell-mediated one. All patients, exposed to different immunosuppressive drugs, were able to produce specific CD4-activated T cells, after spike proteins stimulation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Local Ethical Committee NP4187.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-023-02868-w","type":"journal-article","created":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T16:01:57Z","timestamp":1686758517000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1598-8317","authenticated-orcid":false,"given":"Federica","family":"Filippini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Giacomelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7710-6693","authenticated-orcid":false,"given":"Chiara","family":"Bazzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6511-4936","authenticated-orcid":false,"given":"Micaela","family":"Fredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7053-3086","authenticated-orcid":false,"given":"Paolo","family":"Semeraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3699-8744","authenticated-orcid":false,"given":"Cesare","family":"Tomasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3678-6124","authenticated-orcid":false,"given":"Franco","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5178-566X","authenticated-orcid":false,"given":"Arnaldo","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2757-7120","authenticated-orcid":false,"given":"Ilaria","family":"Cavazzana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4461-9353","authenticated-orcid":false,"given":"Cinzia","family":"Giagulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,14]]},"reference":[{"key":"2868_CR1","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","volume":"386","author":"JA Singh","year":"2015","unstructured":"Singh JA, Cameron C, Noorbaloochi S, Cullis N, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386:258\u201365.","journal-title":"Lancet"},{"key":"2868_CR2","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","volume":"584","author":"EJ Williamson","year":"2020","unstructured":"Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430\u20136.","journal-title":"Nature"},{"key":"2868_CR3","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","volume":"80","author":"A Strangfeld","year":"2021","unstructured":"Strangfeld A, Sch\u00e4fer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al. COVID-19 Global Rheumatology Alliance. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80:930\u201342. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219498.","journal-title":"Ann Rheum Dis"},{"key":"2868_CR4","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N Engl J Med. 2020;383:2603\u201315.","journal-title":"N Engl J Med"},{"key":"2868_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, Sahly HME, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-Cov2 Vaccine. N Engl J Med. 2021;384:403\u201316.","journal-title":"N Engl J Med"},{"key":"2868_CR6","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1053\/j.ajkd.2019.06.014","volume":"75","author":"KM Krueger","year":"2020","unstructured":"Krueger KM, Ison MG, Ghossein C. Practical Guide to Vaccination in All Stages of CKD, Including Patients Treated by Dialysis or Kidney Transplantation. Am J Kidney Dis. 2020;75:417\u201325.","journal-title":"Am J Kidney Dis"},{"key":"2868_CR7","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/acr.22246","volume":"66","author":"C Hua","year":"2014","unstructured":"Hua C, Barnetche T, Combe B, Morel J. Effect of methotrexate, anti-tumor necrosis factor \u03b1, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2014;66:1016\u201326.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2868_CR8","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/ard.2007.077461","volume":"67","author":"S Oren","year":"2008","unstructured":"Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis. 2008;67:937\u201341.","journal-title":"Ann Rheum Dis"},{"key":"2868_CR9","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.vaccine.2010.12.072","volume":"29","author":"U Arad","year":"2011","unstructured":"Arad U, Tzadok S, Amir S, Mandelboim M, Mendelson E, Wigler I, et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine. 2011;29:1643\u20138.","journal-title":"Vaccine"},{"key":"2868_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/art.25033","volume":"62","author":"S Van Assen","year":"2010","unstructured":"Van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen LA, Voskuyl LE, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 2010;62:75\u201381.","journal-title":"Arthritis Rheum"},{"key":"2868_CR11","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","volume":"383","author":"EE Walsh","year":"2020","unstructured":"Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and Immunogenicity of Two RNA-Based COVID-19 Vaccine Candidates. N Engl J Med. 2020;383:2439\u201350.","journal-title":"N Engl J Med"},{"key":"2868_CR12","doi-asserted-by":"publisher","first-page":"e0244126","DOI":"10.1371\/journal.pone.0244126","volume":"15","author":"N Post","year":"2020","unstructured":"Post N, Eddy D, Huntley C, van Schalkwyk MCI, Shrotri M, Leeman D, et al. Antibody response to SARS-Cov2 infection in humans: A systematic review. PLoS ONE. 2020;15:e0244126.","journal-title":"PLoS ONE"},{"key":"2868_CR13","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","volume":"586","author":"U Sahin","year":"2020","unstructured":"Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586:594\u20139.","journal-title":"Nature"},{"key":"2868_CR14","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","volume":"27","author":"KJ Ewer","year":"2021","unstructured":"Ewer KJ, Barrett JR, Belij-Rammerstorfer S, Flaxman AL, Polegatti PM, Owens DR, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial. Nat Med. 2021;27:270\u20138.","journal-title":"Nat Med"},{"key":"2868_CR15","doi-asserted-by":"crossref","unstructured":"Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell Responses to SARS-Cov2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020;181:1489\u20131501.e15.","DOI":"10.1016\/j.cell.2020.05.015"},{"issue":"6529","key":"2868_CR16","doi-asserted-by":"publisher","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","volume":"371","author":"JM Dan","year":"2021","unstructured":"Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-Cov2 assessed for up to 8 months after infection. Science. 2021;371(6529):eabf4063.","journal-title":"Science"},{"issue":"1","key":"2868_CR17","doi-asserted-by":"publisher","first-page":"e0245532","DOI":"10.1371\/journal.pone.0245532","volume":"16","author":"M Shrotri","year":"2021","unstructured":"Shrotri M, Van Schalkwyk MCI, Post N, Eddy D, Huntley C, Leeman D, et al. T cell response to SARSCov2 infection in humans: a systematic review. PLoS ONE. 2021;16(1):e0245532.","journal-title":"PLoS ONE"},{"key":"2868_CR18","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2598-9","volume":"587","author":"J Braun","year":"2020","unstructured":"Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. SARS-Cov2-reactive T cells in healthy donors and patients with COVID-19. Nature. 2020;587:270\u20134.","journal-title":"Nature"},{"key":"2868_CR19","doi-asserted-by":"publisher","first-page":"eabj1750","DOI":"10.1126\/sciimmunol.abj1750","volume":"6","author":"D Geers","year":"2021","unstructured":"Geers D, Shamier MC, Bogers S, den Hartog G, Gommers L, Nieuwkoop NN, et al. SARS-Cov2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccinees. Sci Immunol. 2021;6:eabj1750.","journal-title":"Sci Immunol."},{"key":"2868_CR20","first-page":"682","volume":"2","author":"S Kalimuddin","year":"2021","unstructured":"Kalimuddin S, Tham CY, Qui M, de Alwis R, Sim JXY, Lim JME, et al. Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset. Med (N Y). 2021;2:682-688.e4.","journal-title":"Med (N Y)"},{"key":"2868_CR21","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685\u201399.","journal-title":"Ann Rheum Dis"},{"key":"2868_CR22","doi-asserted-by":"publisher","first-page":"900","DOI":"10.4049\/jimmunol.166.2.900","volume":"166","author":"S Fiorentini","year":"2001","unstructured":"Fiorentini S, Licenziati S, Alessandri G, Castelli F, Caligaris S, Bonafede M, et al. CD11b Expression Identifies CD8+CD28+ T Lymphocytes with Phenotype and Function of Both Naive\/Memory and Effector Cells. J Immunol. 2001;166:900\u20137.","journal-title":"J Immunol"},{"key":"2868_CR23","doi-asserted-by":"publisher","first-page":"580987","DOI":"10.3389\/fimmu.2020.580987","volume":"11","author":"C Tincati","year":"2020","unstructured":"Tincati C, Cannizzo ES, Giacomelli M, Badolato R, D\u2019Arminio Monforte A, et al. Heightened Circulating Interferon-Inducible Chemokines, and Activated Pro-Cytolytic Th1-Cell Phenotype Features Covid-19 Aggravation in the Second Week of Illness. Front Immunol. 2020;11:580987.","journal-title":"Front Immunol"},{"key":"2868_CR24","doi-asserted-by":"publisher","first-page":"102927","DOI":"10.1016\/j.autrev.2021.102927","volume":"21","author":"A Jena","year":"2022","unstructured":"Jena A, Misha S, Deepak P, Kumar-M P, Sharma A, Patel YI, et al. Response to SARS-Cov2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis. Autoimmun Rev. 2022;21:102927.","journal-title":"Autoimmun Rev"},{"key":"2868_CR25","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","volume":"80","author":"V Furer","year":"2021","unstructured":"Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levarstovsky D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis. 2021;80:1330\u20138.","journal-title":"Ann Rheum Dis"},{"key":"2868_CR26","doi-asserted-by":"publisher","first-page":"e001898","DOI":"10.1136\/rmdopen-2021-001898","volume":"8","author":"C Sieiro Santos","year":"2022","unstructured":"Sieiro Santos C, CallejaAntolin S, Moriano Morales C, Garcia Herrero J, Diez Alvarez E, Ramos Ortega F, et al. Immune responses to mRNA vaccines against SARS-Cov2 in patients with immune-mediated inflammatory rheumatic diseases. RMD Open. 2022;8:e001898.","journal-title":"RMD Open"},{"key":"2868_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/art.42153","author":"SW Syversen","year":"2022","unstructured":"Syversen SW, Jyssum I, Tveter AT, Tran TT, Sexton J, Provan SA, et al. Immunogenicity and safety of standard and third-dose SARS\u2013CoV-2 vaccination in patients receiving immunosuppressive therapy. Arthritis Rheumatol. 2022. https:\/\/doi.org\/10.1002\/art.42153.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"2868_CR28","doi-asserted-by":"publisher","first-page":"e202201381","DOI":"10.26508\/lsa.202201381","volume":"5","author":"E Azzolini","year":"2022","unstructured":"Azzolini E, Pozzi C, Germagnoli L, Oresta B, Carriglio N, Calleri M, et al. mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients. Life Sci Alliance. 2022;5(6):e202201381. https:\/\/doi.org\/10.26508\/lsa.202201381.","journal-title":"Life Sci Alliance."},{"key":"2868_CR29","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/BF02849902","volume":"24","author":"L Lundquist","year":"2007","unstructured":"Lundquist L. Abatacept: A novel therapy approved for the treatment of patients with rheumatoid arthritis. Adv Ther. 2007;24:333\u201345.","journal-title":"Adv Ther"},{"key":"2868_CR30","first-page":"2162","volume":"33","author":"MH Weisman","year":"2006","unstructured":"Weisman MH, Durez P, Hallegua D, Aranda R, Becker JC, Nuamah I, et al. Reduction of Inflammatory Biomarker Response by Abatacept in Treatment of Rheumatoid Arthritis. J Rheumatol. 2006;33:2162\u20136.","journal-title":"J Rheumatol"},{"key":"2868_CR31","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1681\/ASN.V132559","volume":"13","author":"A Yamada","year":"2002","unstructured":"Yamada A, Salama AD, Sayegh MH. The Role of Novel T Cell Costimulatory Pathways in Autoimmunity and Transplantation. J Am Soc Nephrol. 2002;13:559\u201375.","journal-title":"J Am Soc Nephrol"},{"key":"2868_CR32","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/1074-7613(95)90000-4","volume":"2","author":"JA Bluestone","year":"1995","unstructured":"Bluestone JA. New perspectives of CD28-B7-mediated T cell costimulation. Immunity. 1995;2:555\u20139.","journal-title":"Immunity"},{"key":"2868_CR33","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1084\/jem.174.3.561","volume":"174","author":"PS Linsley","year":"1991","unstructured":"Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991;174:561\u20139.","journal-title":"J Exp Med"},{"key":"2868_CR34","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/1074-7613(94)90071-X","volume":"1","author":"TL Walunas","year":"1994","unstructured":"Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1:405\u201313.","journal-title":"Immunity"},{"key":"2868_CR35","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1084\/jem.183.6.2541","volume":"183","author":"TL Walunas","year":"1996","unstructured":"Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks. CD28-dependent T cell activation. J Exp Med. 1996;183:2541\u201350.","journal-title":"J Exp Med."},{"key":"2868_CR36","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1136\/annrheumdis-2015-208887","volume":"75","author":"C Clavel","year":"2016","unstructured":"Clavel C, Ceccato L, Anquetil F, Serre G, Sebbag M. Among human macrophages polarised to different phenotypes, the M-CSF-oriented cells present the highest pro-inflammatory response to the rheumatoid arthritis-specific immune complexes containing ACPA. Ann Rheum Dis. 2016;75:2184\u201391.","journal-title":"Ann Rheum Dis"},{"key":"2868_CR37","first-page":"367","volume":"37","author":"L Tweehuysen","year":"2019","unstructured":"Tweehuysen L, den Broeder AA, Schraa K, Netea MG, van der Hoogen FHJ, Joosten LAB. Predictive value of ex-vivo drug-inhibited cytokine production for clinical response to biologic DMARD therapy in rheumatoid arthritis. Clin Exp Rheum. 2019;37:367\u201372.","journal-title":"Clin Exp Rheum"},{"key":"2868_CR38","first-page":"956","volume":"38","author":"K Yukava","year":"2020","unstructured":"Yukava K, Mokuda S, Kohno H, Oi K, Kuranobu T, Tokunaga T, et al. Serum CXCL10 levels are associated with better responses to abatacept treatment of rheumatoid arthritis. Clin Exp Rheum. 2020;38:956\u201363.","journal-title":"Clin Exp Rheum"},{"key":"2868_CR39","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1084\/jem.166.4.1084","volume":"166","author":"AD Luster","year":"1987","unstructured":"Luster AD, Ravetch JV. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J Exp Med. 1987;166:1084\u201397.","journal-title":"J Exp Med"},{"key":"2868_CR40","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/icb.2010.158","volume":"89","author":"JR Groom","year":"2011","unstructured":"Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol. 2011;89:207\u201315.","journal-title":"Immunol Cell Biol"},{"key":"2868_CR41","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00296-004-0449-x","volume":"25","author":"A Ueno","year":"2005","unstructured":"Ueno A, Yamamura M, Iwahashi M, Okamoto A, Aita T, Ogawa N, et al. The production of CXCR3-agonistic chemo-kines by synovial fibroblasts from patients with rheumatoid arthritis. Rheumatol Int. 2005;25:361\u20137.","journal-title":"Rheumatol Int"},{"key":"2868_CR42","doi-asserted-by":"publisher","first-page":"R176","DOI":"10.1186\/ar2865","volume":"11","author":"M Cutolo","year":"2009","unstructured":"Cutolo M, Soldano S, Montagna P, Sulli A, Seriolo B, Cimmino MA, et al. CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production. Arthritis Res Ther. 2009;11:R176.","journal-title":"Arthritis Res Ther"},{"issue":"20","key":"2868_CR43","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13075-018-1527-x","volume":"7","author":"A Bozec","year":"2018","unstructured":"Bozec A, Luo Y, Engdahl C, Figueiredo C, Bang H, Schett G. Abatacept blocks anti-citrullinated protein antibody and rheumatoid factor mediated cytokine production in human macrophages in IDO-dependent manner. Arthritis Res Ther. 2018;7(20):24.","journal-title":"Arthritis Res Ther"},{"key":"2868_CR44","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.cmi.2021.10.006","volume":"28","author":"Y Chen","year":"2022","unstructured":"Chen Y, Yin S, Tong X, Tao Y, Ni J, Pan J, et al. Dynamic SARS-CoV-2 specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine. Clin Microbiology and Infection. 2022;28:410\u20138.","journal-title":"Clin Microbiology and Infection"},{"key":"2868_CR45","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41586-021-03841-4","volume":"597","author":"V Oberhardt","year":"2021","unstructured":"Oberhardt V, Luxenburger H, Kemming J, Schuljen I, Ciminski K, Giese S, et al. Rapid and stable mobilization of CD8+ T cells by SARS-Cov2 mRNA vaccine. Nature. 2021;597:268\u201373.","journal-title":"Nature"},{"key":"2868_CR46","doi-asserted-by":"publisher","first-page":"911","DOI":"10.3899\/jrheum.091176","volume":"37","author":"M Scarsi","year":"2010","unstructured":"Scarsi M, Ziglioli T, Airo\u2019 P. Decreased Circulating CD28-negative T Cells in Patients with Rheumatoid Arthritis Treated with Abatacept Are Correlated with Clinical Response. J Rheumatol. 2010;37:911\u20136.","journal-title":"J Rheumatol."},{"key":"2868_CR47","doi-asserted-by":"publisher","first-page":"6894374","DOI":"10.1155\/2017\/6894374","volume":"2017","author":"S Dulic","year":"2017","unstructured":"Dulic S, Vasarhelyi Z, Sava F, Berta L, Szalay B, Toldi G, et al. T-Cell Subsets in Rheumatoid Arthritis Patients on Long-Term Anti-TNF or IL-6 Receptor Blocker Therapy. Mediators Inflamm. 2017;2017:6894374.","journal-title":"Mediators Inflamm"},{"key":"2868_CR48","doi-asserted-by":"publisher","unstructured":"Madelon N, Lauper K, Breville G, Sabater Royo I, Goldstein R, Andrey DO, et al. Robust T cell responses in anti-CD20 treated patients following COVID-19 vaccination: a prospective cohort study. Clin Infect Dis. 2021; Nov 17. https:\/\/doi.org\/10.1093\/cid\/ciab954.","DOI":"10.1093\/cid\/ciab954"},{"issue":"13","key":"2868_CR49","doi-asserted-by":"publisher","first-page":"901055","DOI":"10.3389\/fimmu.2022.901055","volume":"17","author":"D Mauro","year":"2022","unstructured":"Mauro D, Ciancio A, Di Vico C, Passariello L, Rozza G, Pasquale MD, et al. Serological response to BNT162b2 anti-SARS-CoV-2 vaccination in patients with inflammatory rheumatic diseases: results from the RHEUVAX Cohort. Front Immunol. 2022;17(13):901055.","journal-title":"Front Immunol"},{"key":"2868_CR50","doi-asserted-by":"publisher","first-page":"6333","DOI":"10.4049\/jimmunol.176.10.6333","volume":"176","author":"JE McElhaney","year":"2006","unstructured":"McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol. 2006;176:6333\u20139.","journal-title":"J Immunol"},{"key":"2868_CR51","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1016\/j.vaccine.2009.01.136","volume":"27","author":"JE McElhaney","year":"2009","unstructured":"McElhaney JE, Ewen C, Zhou X, Kane KP, Xie D, Hager WD, et al. Granzyme B: correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine. 2009;27:2418\u201325.","journal-title":"Vaccine"},{"key":"2868_CR52","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41577-020-00436-4","volume":"20","author":"RJ Cox","year":"2020","unstructured":"Cox RJ, Brokstad KA. Not just antibodies: B cells and T cells mediate immunity to COVID-19. Nat Rev Immunol. 2020;20:581\u20132.","journal-title":"Nat Rev Immunol"},{"key":"2868_CR53","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1038\/s41591-020-0995-0","volume":"26","author":"JA Juno","year":"2020","unstructured":"Juno JA, Tan HX, Lee WS, Reynaldi A, Kelly HG, Wragg K, et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat Med. 2020;26:1428\u201334.","journal-title":"Nat Med"},{"key":"2868_CR54","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jaci.2020.04.013","volume":"146","author":"I Quinti","year":"2020","unstructured":"Quinti I, Lougaris V, Milito C, Cinetto F, Pecoraro A, Mezzaroma I, et al. A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. J Allergy Clin Immunol. 2020;146:211-213.e4.","journal-title":"J Allergy Clin Immunol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-023-02868-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-023-02868-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-023-02868-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T17:02:38Z","timestamp":1686762158000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-023-02868-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,14]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2868"],"URL":"https:\/\/doi.org\/10.1186\/s12916-023-02868-w","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,14]]},"assertion":[{"value":"12 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Local Ethical committee approved the study (code NP 4187). All the patients and HC gave the consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors consent to the present publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"210"}}